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Abstract
Breast cancer is a heterogeneous disease that affects close to two million
women each year. Of these women, seventy percent express estrogen receptor
alpha, a member of the nuclear receptor subfamily that is activated in response to
estrogen. Our research has shown an alternate mechanism by which estrogen
receptor alpha is activated and subsequently elicits its cancer promoting effects.
The process of glycation involves the non-enzymatic addition of sugar
moieties to biological macromolecules which produce reactive metabolites known
as advanced glycation end products (AGEs). These metabolites have been shown to
be responsible for many of the complications associated with diabetes because of
their ability to interact with the Receptor for Advanced Glycation End Products
(RAGE) and produce a chronic inflammatory phenotype. Similarly, this same effect
has been shown in several different cancers including prostate, melanoma, and
colorectal.
Like other cancers, we observed greater levels of AGEs and RAGE within
breast cancer tumor and serum samples and showed a correlation between tumor
progression and intratumoral AGE concentration. Utilizing two ER positive breast
cancer cell lines, T47D and MCF7, we have also identified a role for AGEs in the
phosphorylation of the estrogen receptor at two different residues within the ligand
independent activation domain: serine 118 and serine 167. By utilizing exogenous
AGE treatment and inhibition with molecular inhibitors, we showed that, following
exposure to AGEs, a signaling cascade occurs through Akt and ERK to phosphorylate
iv

these two residues. Additionally, this signaling pathway produced a more
proliferative phenotype in our cell lines. We were able to verify that AGE treatment
was inducing this increase in proliferation through interaction with RAGE by using
shRNA technology.
Activation of the estrogen receptor at these particular residues has been
shown to be indicative of tamoxifen resistance. We identified a role for AGEs in
tamoxifen resistance by performing a cell viability assay and found that AGE treated
cells were indeed less sensitive to drug treatment. Elucidating a role for AGE-RAGE
signaling in breast cancer creates potential for improved therapies and preventative
interventions for patients with the disease.

v

Table of Contents:
Abstract

i

List of Tables

v

List of Figures

vi

List of Abbreviations

viii

Acknowledgements

x

Background and Introduction

1

Breast Cancer

1

Breast Cancer Incidence/Risk Factors

3

Non-Modifiable Risk Factors

3

Modifiable Risk Factors

4

Estrogen Receptor Positive Breast Cancer

5

Estrogen Receptor Alpha

6

Estrogen Receptor Signaling

8

Genomic Action of ERα

8

Non-Genomic Action of ERα

10

Tamoxifen

10

Tamoxifen Resistance

12

Breast Cancer, Obesity, and Diet

15

Advanced Glycation End Products (AGEs)

17

AGE Formation

17

Exogenous Sources of AGEs

20

Receptor for Advanced Glycation End Products (RAGE)

vi

21

AGE-RAGE Signaling in Cancer

23

Clinical Implications of AGEs

24

Inhibition of AGEs

24

AGEs as a Biomarker

25

Disease Prevention

25

Research Plan

26

Overall Rationale

26

Hypothesis

28

Specific Aim #1

28

Experimental Design

29

Results and Conclusion

35

Discussion and Alternative Approaches

43

Specific Aim #2

46

Experimental Design

48

Results and Conclusion

56

Discussion and Alternative Approaches

73

Future Experiments

75

Significance of Study

76

References

78

vii

List of Tables
Table 1: Primer sequences for probe-based qRT-PCR

34

Table 2: Receptor status of serum samples

36

Table 3: shRNA clone sequences

55

viii

List of Figures
Figure 1: Breast anatomy

1

Figure 2: Structure of estrogen receptor alpha

7

Figure 3: ER signaling

8

Figure 4: Tamoxifen mechanism of action

12

Figure 5: Obesity and breast cancer

15

Figure 6: AGE formation

19

Figure 7: RAGE structure

21

Figure 8: AGE-RAGE signaling

23

Figure 9: Proposed signaling pathway

27

Figure 10: AGE serum data

36

Figure 11: GLO1 mRNA in BC cell lines

37

Figure 12: AGE/RAGE IHC quantification

38

Figure 13: IHC images of AGE/RAGE staining

39

Figure 14: AGE/RAGE IHC quantification

41

Figure 15: IHC images of AGE/RAGE staining

42

Figure 16: Endogenous AGE and RAGE analysis

56

Figure 17: Effects of AGE treatment on RAGE expression

57

Figure 18: Proliferation assay and RAGE knockdown

60

Figure 19: Effects of AGE treatment on ER phosphorylation

62

Figure 20: Time dependent AGE treatment on ER phosphorylation

63

Figure 21: Effect of AGE treatment on Akt phosphorylation

65

ix

Figure 22: Effect of AGE treatment on ERK phosphorylation

66

Figure 23: Inhibition of Akt and ER phosphorylation

68

Figure 24: Inhibition of ERK and ER phosphorylation

69

Figure 25: Tamoxifen resistance—MCF7

71

Figure 26: Tamoxifen resistance—T47D

72

x

List of Abbreviations
AGEs—Advanced glycation end products
Akt—Protein kinase B
cDNA—Complimentary DNA
DBD—DNA binding domain
EGFR—Epidermal growth factor receptor
ER—Estrogen receptor
ERE—Estrogen response element
ERK—Extracellular signal regulated kinase
GLO--Glyoxalase
HbA1C—Glycated hemoglobin
HER2—Human epidermal growth factor receptor 2
HMGB1—High mobility group box protein 1
IDC—Invasive ductal carcinoma
IGF-1—Insulin-like growth factor
IGF-1R—Insulin-like growth factor receptor
IHC—Immunohistochemistry
IL-6—Interleukin 6
JNK—c-jun N-terminal kinase
LBD—ligand binding domain
MAPK-mitogen activated protein kinase
MOI—multiplicity of infection
xi

mRNA—messenger RNA
NADPH—Nicotinamide adenine dinucleotide phosphate
NF-κB—nuclear factor kappa-light-chain-enhancer of activated B cells
PI3K—Phosphoinositide 3-kinase
PR—Progesterone receptor
RAGE—Receptor for advanced glycation end products
RT-PCR—Real time polymerase chain reaction
SERD—selective estrogen receptor downregulator
SERM—selective estrogen receptor modulator
SRB—Sulforhodamine B
SRC-3—Nuclear receptor coactivator 3
TMA—Tissue microarray
TNFα—Tumor necrosis factor alpha
UPL—Universal probe library
VEGF—Vascular endothelial growth factor

xii

Acknowledgements
My passion for cancer research would have never been discovered if it weren’t for the
unfailing guidance of my mentor, Dr. David Turner. Thank you for welcoming me into
your lab despite my lack of experience and forcing me to think independently, like a
true scientist. Because of you, I feel as though I am more than ready for what lies ahead
in my career and truly cannot thank you enough.

Additionally, I would like acknowledge Dr. Victoria Findlay and the members of her lab
for their continued support. Whether it simply be sharing reagents for experiments or
career advice during some stressful moments, this research would not have been
possible without the Findlay lab’s guidance. In addition to the Findlay lab, thank you to
the other members of advisory committee, Dr. Laura Spruill and Dr. Steven Rosenzweig,
for taking the time out of your very busy schedules to spend hours meeting with me as
well as reading and critiquing my work. I know I will be a better research scientist
because of both your guidance and support. Finally, thank you the department of
Pathology and Laboratory Medicine at the Medical University of South Carolina for
making this experience possible.

This project was funded by: NIH R21 CA176135 (P.I. Turner)

xiii

Introduction and Background
Breast cancer: Breast cancer is a carcinoma (or sarcoma, in extremely rare cases)
that originates in the breast; which is the structure responsible for milk production
and transport following childbirth. The breast is comprised of milk producing
lobules that are grouped together into 15-20 grape-like clusters known as lobes.
During lactation, milk is transported from the lobes and out the nipple through a
network of thin, tube-shaped structures called ducts (Figure 1). Fibrous tissue as
well as fat surround the lobes and ducts to make up the bulk of the breast.

Figure 1. Anatomy of the breast, showing the lobules and ductal system where most
breast cancers originate. Figure adapted from “Three-Dimensional In Silico Breast
Phantoms for Multimodal Image Simulations” by D. Mahr et al, 2012, IEEE
Transactions on Medical Imaging. 31(3):10.1109/TMI.2011.2175401. Copyright 2012
by The Institute of Electrical and Electronics Engineers. Adapted with permission (2).
<EndNote><Cite><Author>Mahr</Author><Year>2012</Year><RecNum>127</Rec
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Additionally, the breast contains blood and lymphatic vessels which play a key role
in tumor metastasis in breast cancer patients. Around 70% of all breast cancers
begin within the ducts, whereas only around 10-15% begin within the lobules
(American Cancer Society). Mammary cells are undifferentiated until lactation
following childbirth and regress to a less differentiated state after menopause. This
lack of differentiation causes the breast to be more susceptible to cancer promoting
stimuli and tumorigenic transformation (7)
There exist several different methods by which cancerous tissue is detected
within the breast. Preventative screenings such as basic clinical breast exams and
mammography are among the most widely used(8). These tests serve to examine
and detect any abnormalities within the breast tissue. If a suspicious mass is found,
a biopsy is then performed to determine malignancy status. Cancerous tumors are
then further characterized using methods such as immunohistochemistry in order
to classify the cancer into a variety of subtypes which will then warrant a specific
treatment regimen(8).
A key issue in treating breast cancer is its vast heterogeneity. A particular
tumor will respond to treatment differently than others, emphasizing the need for
more personalized treatment. Relatively recently, genomic analysis has allowed for
tumors to be classified into molecular subtypes based on the expression of a variety
of genes (BRCA1/2, ERBB2, TP53, etc.). Many unique subtypes have been identified
such as the luminal cancers (A and B), HER2 Enriched, and Basal-like. While our
knowledge base continues to expand, genetic testing is expensive and not readily
2

available in the clinical setting(9). A key portion of the current diagnostic process in
breast cancer is to determine a tumor’s receptor status using
immunohistochemistry (IHC). IHC is relatively inexpensive and aims to characterize
the tumor based on the expression of three different receptors: estrogen receptor
(ER), progesterone receptor (PR), and the human epidermal growth factor receptor
2 (HER2). Knowing a tumor’s receptor status is crucial in the formation of a
patient’s treatment plan because receptor expression allows for targeted therapies
that disrupt tumorigenic signaling, resulting in inhibition of cancer growth and
survival. By characterizing these tumors, treatment is more personalized for the
patient’s particular cancer, leading to an improved prognosis.

Breast Cancer Incidence/Risk Factors: Breast cancer is a disease that affects postpubescent women of all ages. Annually affecting 1.7 million worldwide, the
incidence of breast cancer has steadily increased within the past decade and is only
expected to continue to rise (9). In the U.S. alone, over 200,000 new cases are
diagnosed each year with around 40,000 deaths attributed to the disease (American
Cancer Society). Because of its breadth, breast cancer does indeed represent a
substantial health burden and certain factors have been shown to modify a person’s
risk of incidence, reoccurrence, and mortality of the disease.
Non-Modifiable Risk Factors: The most influential risk factor associated
with breast cancer development, other than gender, is age. Fewer than 10%
of all invasive breast cancers are diagnosed in women under 40, with the
3

greatest risk present in post-menopausal women, peaking around age 70 (8).
In addition to age, heritable genetic mutations have been shown to cause
around 5-10% of all breast cancers (10). Research looking into the effects of
gene mutations such as BRCA1, BRCA2, and TP53 (among many others) has
allowed for preventative intervention and patient specific care. Another
studied risk factor is race and ethnicity. Post-menopausal Caucasian women
have the highest risk of breast cancer development. While the overall
incidence is lower in the African American population, women of this race
have an increased risk of developing a more aggressive disease at a younger
age, resulting in a higher mortality rate (11).
Lifestyle Risk Factors: Certain factors that are modifiable also influence the
risk of disease development. There is evidence that suggests weight gain and
obesity, particularly following menopause, increases the risk of incidence,
reoccurrence, and mortality of breast cancer (12-14). Relatedly, diet has been
associated with increased incidence as well, which will be discussed in
further detail later. Other risk factors are attributed to either lack of
differentiation (i.e. nulliparous, non-breastfeeding, etc.) which leaves the
mammary tissue more susceptible to transformation, or to exogenous
hormones found in oral contraceptives or hormone replacement therapy (15,
16).
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Estrogen Receptor Positive Breast Cancer: As stated previously, subtyping of
breast cancers is imperative in developing the most effective treatment plan for
patients. Genomic testing is not widely used in the clinic so IHC classification is a
staple in the diagnostic process. Of all invasive breast cancers, around 70% express
the estrogen receptor (17). These ER+ breast cancers are included in the Luminal
molecular subtypes. Around 50-60% of breast cancers are Luminal A and have the
best prognosis of all the subtypes. These tumors are generally ER+, PR+/-, and
HER2- and have a low proliferation score, measured by Ki-67 staining. Luminal B
tumors are generally ER+, PR+/- as well, but can also express the HER2 growth
factor receptor. Additionally, these tumors usually have a high proliferation score,
resulting in a worsened prognosis. While the correlation between pathological and
molecular subtypes is not infallible, the overlap between the two diagnostic
procedures allows for better insight into the characteristics of a patient’s specific
tumor. ER+ breast cancers tend to have an improved prognosis, not only because
these tumors generally present with lower histological grades and little-to-no lymph
node involvement at diagnosis, but also because expression of the estrogen receptor
makes a patient a candidate for targeted therapies (9, 18). In ER+ positive breast
cancer, there are two main categories of treatment: anti-estrogens and aromatase
inhibitors. Anti-estrogens, which block the functionality of the receptor, can be
further subdivided into selective estrogen receptor downregulators (SERD) and
selective estrogen receptor modulators (SERM). SERDs act as full antagonists
toward the receptor by causing ER degradation, whereas SERMs can function in an
5

antagonistic or agonistic manner, depending upon the targeted tissue location.
Aromatase inhibitors, which are most often prescribed secondary to anti-estrogens
in post-menopausal women, block the functionality of the enzyme aromatase which
is responsible for converting testosterone to estrogen. Blocking the production of
the ligand therefore hinders ER mediated signaling. These aromatase inhibitors,
while effective, do exhibit greater toxicity when compared to anti-estrogens,
especially in premenopausal women (19).

Estrogen Receptor Alpha: The estrogen receptors are a group of nuclear receptors
that are included in the subfamily of ligand activated transcription factors (20).
Currently, two receptors are known: ERα and ERβ. These receptors are the product
of unique genes and differ in their functionality and structure. The ligand and DNA
binding domains of these receptors have been evolutionarily conserved, resulting in
a great amount of homology between the two receptors in these regions. The ligand
independent region located at the N-terminus of each receptor, however, varies
markedly (21, 22). Despite it being the subject of research for over a decade, the
exact functionality of ERβ remains unknown (23). Because of this, ERα (Figure 2) is
the isoform detected during immunohistochemical analysis and subsequently used
for diagnostic and therapeutic purposes in breast cancer.
Structurally, ERα consists of three main functional domains (Figure 2).
Because of its transcription factor functionality, ERα contains a DNA binding domain
(DBD). The DBD is responsible for binding to the estrogen response element (ERE)
6

within the promoter sequence on the DNA of its target genes to enhance
transcription. ERα also contains a ligand binding domain (LBD) where estrogens can
interact and enhance DNA binding (21). This ligand dependent activation of ERα has
been widely studied. Relatively recently, however, activation of ERα has been shown
to occur independently of ligand via second messengers (20). These second
messengers interact with the N-terminus of the receptor within the ligand
independent domain to induce ERα DNA binding.

Figure 2. Structure of estrogen receptor alpha.

7

Estrogen Receptor Signaling:

Figure 3. Classical and non-classical signaling of ERα. ERα is classically activated by
estrogen which induces receptor dimerization, nuclear localization, and transcription
of target genes. Additionally, growth factor signaling pathways can interact with the
receptor to induce DNA binding. Adapted from “Neuroprotective effects of 17 betaestradiol rely on estrogen receptor membrane initiated signals” by M. Fiocchetti et al,
2012, Frontiers in Physiology, 3:73. Copyright 2012 by Fiocchetti, Ascenzi and
Marino. Adapted with permission in accordance with the Creative Commons License
3.0. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319910/ (3).

Genomic (classical) Action of ERα: Because estrogen is a steroid hormone, it is
able to diffuse freely through the plasma membrane and interact with cytoplasmic
estrogen receptors (Figure 3). Once estrogen binds, the receptor undergoes several
conformational changes that allow it to dissociate from chaperone proteins and
8

dimerize(19). Following translocation to the nucleus, the dimerized receptor can act
in one of two ways. The receptor can bind directly to the estrogen response element
(ERE) located on the promoter region of its target gene and recruit regulatory
proteins such as AIB1 or SRC3, or it can bind to transcription factor complexes such
as AP-1 or NF-κB, thereby enabling it to enhance transcription of genes without an
ERE(24). Target genes of ERα include several proliferative, pro-survival, and
angiogenic factors such as c-myc, VEGF, IGF-1R, among several others(19). Estrogen
mediated signaling is crucially important in the progression and survival of tumors
in ER+ breast cancer.
Estrogen Independent Activation: ERα contains two transcription
activation functional domains: AF1 and AF2. Following estrogen binding to
the ligand binding domain, AF2 (estrogen dependent) synergizes with AF1,
allowing the receptor to change conformation and form a hydrophobic
groove to promote coactivator binding (17). While the AF2 domain is only
able to enhance transcription in the presence of estrogen, the AF1 domain
can be phosphorylated via second messenger pathways which can then
induce an agonistic or antagonistic conformational change. Phosphorylation
of the receptor by either estrogen binding or through secondary kinases then
induces dimerization and subsequent transcriptional activity as described in
the previous section. Phosphorylation is necessary in order for ERα to
influence transcription, regardless of whether or not estrogen is present
(19). Because of the variance in mechanisms behind the different
9

phosphorylation sites, this particular post-translational modification has
been studied to determine if there is an influence on clinical outcomes in
patients (25).
Non-Genomic Action of ERα: The nuclear action of ERα has been well established.
Relatively recently, however, it has been discovered that ERα influences several
signaling pathways throughout the cell. Membrane associated ERα has been shown
to interact and directly phosphorylate membrane bound receptor tyrosine kinases
such as the epidermal growth factor receptor (EGFR) and the insulin-like growth
factor receptor (IGF-1R) following the binding of estrogen(26). In addition, ERα is
able to directly interact with the p85 subunit of phosphoinositide-3 kinase (PI3K)
leading to the activation of the pro-survival Protein kinase B (Akt)(21). While the
mechanisms by which these interactions occur is still controversial, it is evident that
there exists a bi-directional cross-talk between ERα and growth factor signaling
leading to alterations in proliferation and cell survival, especially in breast cancer.

Tamoxifen: As stated previously, treatment for ER+ breast cancer falls under two
categories: anti-estrogens and aromatase inhibitors. Anti-estrogens are most often
the first line of defense following resection of the primary tumor. Among the most
effective anti-estrogens given to patients with ER+ breast cancer is tamoxifen.
Tamoxifen is a selective estrogen receptor modulator that, when metabolized by the
liver, is converted to 4-hydroxy tamoxifen and N-desmethyl 4-hydroxy tamoxifen
which have up to 100 times greater affinity for the estrogen receptor than tamoxifen
10

itself (19). These reactive species then compete with estrogens to bind to the
receptor. When tamoxifen binds to the receptor, dimerization and DNA binding still
occur, but the AF2 domain remains inactive and the conformational change required
for the binding of cofactors does not occur (Figure 4). Transcription of estrogen
receptor target genes is inhibited, resulting in decreased estrogen-mediated tumor
growth. Because tamoxifen is considered a SERM, it possesses a dual
functionality(17). It can function as an agonist in the endometrium and bone while
acting as an antagonist in the mammary tissue of the breast. The efficacy of
tamoxifen in the treatment of ER+ breast cancer has been well established, and
because it has relatively low toxicity and is able to be given to both pre- and postmenopausal women, it has become the drug of choice for most patients(6).
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Figure 4. Tamoxifen mechanism of action. Tamoxifen competes with estrogen to
bind to ER leading to dimerization and DNA binding. The AF2 domain remains
inactive, inhibiting interaction with transcriptional cofactors. Adapted from
“Tamoxifen (‘Nolvadex’): a Review by M. Clemons and A. Howell, 2002, Cancer
Treatment Reviews, 28(4): 165-180. Copyright 2002 by Elsevier Science Ltd.
Adapted with permission (6).

Tamoxifen resistance: Despite encouraging results in many patients, around 30%
of women taking tamoxifen will not receive benefit from treatment despite still
expressing the estrogen receptor and are considered de novo resistant. In addition
to de novo resistance, almost all patients with metastatic disease will eventually
acquire a resistance to tamoxifen, usually relapsing within 1-2 years (25-27). These
patients are then given second- and third-line treatments in the form of SERDs
12

and/or aromatase inhibitors, but even then, these tumors will most often still
acquire a resistance to these drugs (28). Because of the prevalence of ER+ breast
cancer, it is imperative to identify the mechanism behind the development of
tamoxifen resistance in order to better improve first-line therapies for these
patients. Identification of this mechanism is widely studied but very controversial
and currently there are four theories as to how this resistance occurs: 1) resistance
to specific anti-estrogens (i.e. inability to convert tamoxifen to reactive metabolites),
2) loss of ERα expression, 3) altered ERα signaling, and 4) ligand independent
activation of ERα (28, 29). Phosphorylation within the AF1 domain of ERα
independent of estrogen is thought to contribute to tamoxifen resistance because
transcription is still able to occur despite the absence of ligand. Among the most
widely studied phosphorylation sites within the ligand independent activation
domain are serine 167 and serine 118. These two residues are emerging as potential
predictive markers for patient response to tamoxifen because of their influence on
the structure and functionality of ERα. Ser118 has been shown to be
phosphorylated in response to the activation of several kinase pathways including
the mitogen activated protein kinases (MAPK) ERK 1/2 and p38 (30). Functionally,
phosphorylation of ERα at ser118 by MAPK serves to not only enhance binding of
cofactor SRC-3, but also causes the receptor to become hypersensitive to estradiol,
therefore lowering its affinity for tamoxifen(17). Furthermore, one study utilized a
tamoxifen resistant breast cancer cell line and found that MAPK activity was
significantly increased (31). This activation of MAPK (and subsequent ERα
13

phosphorylation) can either be estrogen dependent or estrogen independent (25).
Ser167 is also phosphorylated by a variety of kinases, most notably by Protein
Kinase B (Akt) within the PI3K signaling pathway (30). Like ser118,
phosphorylation at this residue can occur with or without the estrogen ligand
making it a potential contributor to tamoxifen resistance. While the specific
mechanism by which ser167 influences tamoxifen resistance is currently
understudied, investigators have shown that phosphorylation of this residue by Akt
results in the increased recruitment of cofactors to ERα resulting in enhanced
transcription (30, 32). The MAPK and PI3K signaling cascades are frequently
upregulated in several cancers because of their proliferative and pro-survival
effects. This could potentially be leading to an upregulation of ERα mediated
signaling, independent of estrogen. In an effort to combat tamoxifen resistance,
inhibitors of these pathways in combination with endocrine therapies have been
tested and some have proven to be relatively effective (33). The sheer complexity of
ERα signaling, however, allows the tumor the ability to adapt to even the most
effective drugs (34). Because of this, understanding the complete mechanism by
which tumors become resistant is important in identifying an appropriate and
effective drug target.

14

Figure 5: Interaction between obesity and breast cancer progression. Adipose tissue
possesses endocrine functionality, resulting in increased circulating estrogen which
can promote tumorigenic signaling in ER+ tumors. Adapted from “Obesity and breast
cancer prognosis: weight of the evidence” by F. Sinicrope and A. Dannenberg, 2011,
Journal of Clinical Oncology, 29(3): 4-7. Copyright 2011 by the American Society of
Clinical Oncology. Adapted with permission (4).

Breast Cancer, Obesity, and Diet: As stated previously, poor diet and obesity are
modifiable risk factors contributing to the incidence, reoccurrence, and mortality of
breast cancer in women. Several epidemiological studies have shown an association
between increased adiposity and poorer prognoses, increased incidence, and a
greater mortality rate, especially among post-menopausal women (15). This is
potentially caused by the dual functionality of adipose tissue in both metabolism
and hormone production (Figure 5). Whereas pre-menopausal women produce
15

estrogen primarily in the ovaries, postmenopausal women are restricted to
peripheral sources of estrogen production. Adipose tissue contains aromatase,
which is a complex of enzymes that is responsible for converting androgens
produced in the adrenal gland into estrogen(35). Increased adipose tissue leads to
greater amounts of circulating estrogen, which is a major fuel for ER+ breast
cancers. In addition to production of estrogen, obesity can also cause insulin
resistance leading to glucose intolerance and increased production and secretion of
pro-inflammatory markers such as IL-6 and TNFα (36).
It is no secret that one of the primary causes of obesity is a poor diet. Because
of this, several types of diets (i.e. high fat, high carbohydrate, Mediterranean, etc.)
have been studied to determine what diet in particular has the greatest effect on
breast cancer development and prognosis. Of particular interest for this proposal is
a study utilizing the Italian portion of the European Prospective Investigation into
Cancer and nutrition (EPIC) cohort that looked at the effects of diets with a high
glycemic load on breast cancer incidence in over 26,000 women over eleven years.
After controlling for several external factors such as menopausal status and total
energy intake, the investigators found that women consuming diets high in
carbohydrates, measured by glycemic load, had a significantly increased incidence
of breast cancer development(37). Glycemic load measures both the quality and
quantity of a particular food (unlike glycemic index which just measures quality)
making it a more accurate estimation of post-prandial circulating glucose and
insulin demand. This is especially relevant for cancer because of insulin’s ability to
16

interact with transmembrane receptors and increase proliferation. Furthermore, as
stated previously, activated receptor tyrosine kinases (including IGFRs) can result in
estrogen-independent activation of ERα (15). In addition to the EPIC cohort study,
other epidemiological studies have also looked at glucose metabolism in breast
cancer incidence, including one study investigating fasting blood glucose in a cohort
of over 10,000 women. After a five year period, 144 breast cancer cases were
matched with 4 control participants who did not develop breast cancer over the
examination period. The investigators found that in post-menopausal women,
glucose, insulin, and IGF-1 were all associated with increased breast cancer
incidence, leading the investigators to conclude that altered glucose metabolism is a
risk factor for breast cancer development (38).

Advanced Glycation End Products: Persistently high levels of glucose within the
blood, often resulting from a carbohydrate-rich diet, not only alters insulin mediated
signaling, but also leads to the increased formation of reactive metabolites known as
advanced glycation end products (AGEs)(39).

AGE Formation: This heterogeneous, complex group of molecules is formed
during normal metabolism, classically through what’s known as the Maillard,
or browning, reaction (40) (Figure 6). This AGE-forming reaction occurs in a
series of three phases. The first step is glycation, which is the non-enzymatic
addition of reducing sugars to the amino groups on biological
17

macromolecules such as proteins, lipids, or nucleic acids to form Schiff bases.
This first step is reversible and its initiation is heavily dependent upon sugar
concentration. The second step of the Maillard reaction involves the Schiff
base undergoing a series of rearrangements over the course of a few days to
form Amadori products, or early glycation products. Glycated hemoglobin, or
HbA1C, is an example of an Amadori product that is a widely used
measurement of long-term blood glucose concentration in diabetic patients.
These products are more stable than Schiff bases, but the total reaction is still
reversible at this point. Accumulation of Amadori products, however, causes
an even further series of rearrangements that can take several weeks and
irreversibly forms the reactive, cross-linking proteins known as AGEs (1, 41).
While the Maillard reaction is the classical pathway for AGE formation
within the body, there exist other mechanisms capable of producing these
reactive metabolites. Α-oxoaldehydes (glyoxal, methyglyoxal, etc.) formed
from the autooxidation of monosaccharides or the peroxidation of lipids can
interact with monoacids to form AGEs in high oxidative stress environments
(1). Additionally, these α-oxoaldehydes can be formed through the polylol
pathway in which glucose is converted to fructose intermediates (Figure 6).
The variety of precursors and reactions responsible for the formation of
AGEs are what give this group of reactive metabolites their heterogeneity in
both structure and pathogenic functionality(42).
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Figure 6. Formation of AGEs. Endogenous formation of AGEs can occur through a
variety of mechanisms. Classical formation occurs through the Maillard (Browning)
reaction but AGEs can also be formed through autooxidation of glucose, peroxidation
of lipids, and the polyol pathway. Adapted from “Dietary Advanced Glycation End
Products and Aging” by C. Luevano-Contreras and K. Chapman-Novakofski, 2010,
Nutrients, 2(12):1247-1265. Copyright 2010 by C. Luevano-Contreras and K.
Chapman-Novakofski. Adapted with permission in accordance with the Creative
Commons License 4.0, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257625/
(1).

One of the key internal mechanisms inhibiting AGE formation is the
glyoxalase system (GLO). GLO is responsible for detoxifying methylglyoxal, a
reactive carbonyl and AGE precursor (43). This is accomplished by catalyzing
the conversion of methylglyoxal to lactate and is a process that has been
shown to be very active in cancer because of the high rate of glycolysis and
glucose consumption that is characteristic of the tumor microenvironment
(44).
19

Exogenous Sources of AGEs: In addition to normal metabolism, AGEs are
naturally present in uncooked, animal derived foods. Furthermore, particular
food preparations can increase the AGE content of a food by driving AGE
forming reactions. Cooking methods involving dry heat such as grilling,
broiling, and searing induce the greatest AGE forming effect (40). Thermal
processing for food safety and/or preservation purposes can also increase
the AGE content of a particular food. AGEs themselves can even be added to
food in order to enhance taste, appearance, and color (45, 46).
The western diet generally refers to a diet high in fat, sugar, and
processed foods and is a key contributor in the dramatic increase in rates of
both obesity and type 2 diabetes. These foods, coincidentally, are also high in
AGE content. The exact fraction of exogenous AGEs being successfully
absorbed remains controversial, but several studies have found a postprandial increase in serum AGE levels several days following consumption of
an AGE rich meal, suggesting that these reactive molecules can indeed
contribute to overall AGE accumulation with the body (47). Because cellular
and renal clearance of AGEs is inefficient, increased consumption of these
foods leads to an increase in the deleterious effects associated with this
reactive species that can potentially worsen overtime (40, 42).
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Receptor for Advanced Glycation End
Products (and pathogenic signaling):
AGEs can contribute to pathogenesis in one
of two ways. They can act independently of a
receptor and cause damage to protein
structure and function, particularly within
the extracellular matrix by causing collagen
crosslinking, or by acting as a ligand for the
receptor for advanced glycation end
products (RAGE) (1). RAGE is a
Figure 7: RAGE structure showing
functional domains. Adapted from
“Receptor for Advanced Glycation
End Products and Atherosclerosis:
from Basic Mechanisms to Clinical
Implications” by G. Basta, 2008,
Atherosclerosis, 196(1):9-21.
Copyright 2008 by Elsevier Science
Ltd. Adapted with permission (5).

transmembrane, pattern recognition
receptor that is part of the immunoglobulin
superfamily (48) (Figure 7). It is expressed
in relatively low levels in all tissues on
multiple cell types throughout the body, but

is found to be greatly increased in pathophysiological settings (i.e. hypoxic and
inflammatory environments) (49). Structurally, RAGE contains a variable domain
that is responsible for ligand binding, two constant domains, a transmembrane
domain, and a cytoplasmic domain responsible for carrying out RAGE intracellular
signaling. In addition to binding AGEs, RAGE also interacts with a variety of other
ligands including the S100 family of proteins and High Mobility Group Box Protein 1
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(HMGB1). Because of the variety of its ligands, RAGE signaling encompasses several
different pathways involved in the inflammatory and immune responses (42).
A key effector in the propagation of the inflammatory response following
injury is the activation of the transcription factor NF-κB (Figure 8). After AGE binds
RAGE, several downstream signaling pathways are activated including the
phosphatidylinositol-3-kinases (PI3K) and mitogen activated protein kinases
(MAPK) which lead to translocation of NF-κB to the nucleus (1). The transcription
factor then enhances production and subsequent release of inflammatory cytokines,
growth factors, and adhesive molecules which serve to recruit more leukocytes to
the site of injury or infection (Figure 8). Additionally, NF-κB also enhances
transcription of RAGE itself, causing a positive feedback loop with enhanced AGERAGE signaling, resulting in a chronic inflammatory phenotype (1). Because of its
role in inflammation, AGE signaling has been implicated in the progression and
complications of a variety of diseases including diabetes, cardiovascular disease, and
Alzheimer’s (41).
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Figure 8. Pro-inflammatory AGE-RAGE signaling axis. Following ligand
binding, PI3K and MAPK are activated downstream causing translocation to
of NF-κB to nucleus resulting in enhanced transcription and subsequent
release of inflammatory markers. Adapted from “Dietary Advanced Glycation
End Products and Aging” by C. Luevano-Contreras and K. Chapman-Novakofski,
2010, Nutrients, 2(12):1247-1265. Copyright 2010 by C. Luevano-Contreras and K.
Chapman-Novakofski. Adapted with permission in accordance with the Creative
Commons License 4.0, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257625/
(1).

AGE-RAGE Signaling in Cancer: It has been suggested that a proinflammatory environment can serve to promote tumorigenesis (49-51). This
functionality is partly due to the ability of cytokines released during the
inflammatory response to promote un-controlled proliferation(52). Relatively
recently, several studies have shown that AGEs are increased and RAGE is
upregulated in a variety of cancers including prostate, colorectal, and gastric (53). In
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addition, AGE-RAGE signaling has been implicated in several cancer-associated
signaling pathways that are pro-survival and contribute to increased proliferation,
migration, and invasion, leading to a more aggressive phenotype with greater
metastatic potential (54). As stated previously, AGE binding RAGE leads to the
activation of the PI3K and MAPK pathways. Interestingly, these two pathways are
also known to be upregulated or altered in a variety of cancers. Protein kinase B
(Akt), within the PI3K pathway, promotes survival by inhibiting apoptosis and cell
cycle arrest within cancerous cells (55). RAGE binding AGEs can also activate
several different proteins within the MAPK pathway including ERK1/2, JNK, and
p38 which are heavily involved in the growth potential of malignant tumors (48).
The activation of PI3K, MAPK, as well as NADPH oxidase by AGE-RAGE signaling
then activates NF-κB which, as stated previously, causes the enhanced transcription
of not only several inflammatory cytokines and growth factors, but RAGE as well.
This causes a feed-forward, pro-tumorigenic loop, leading to a more aggressive
phenotype in cancer (1).

Clinical Implications of AGEs Implicating AGEs in the progression of several
diseases has led to attempts at identifying a way to utilize these reactive metabolites
in the clinic.
Inhibition of AGEs: It has been widely studied that AGEs are poor
prognostic markers for complications in inflammatory diseases, especially in
diabetes. Relatively recently, however, it has been suggested that AGEs could
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potentially be successful drug targets by either blocking their formation or
inhibiting intracellular signaling. (56). Drugs such as Metformin, which
inhibits formation of AGEs are already being clinically utilized for treatment
of other chronic diseases and could be potentially helpful as a dual therapy in
AGE-associated cancer (57).
AGEs as a biomarker: In diabetes and cardiovascular disease, assessing AGE
content in patient serum and tissue has proved valuable in predicting
complications associated with these diseases. In diabetes, high levels of AGEs
are shown to be predictive of microvascular complication and nephropathy
(58). Interestingly, AGEs seem to have greater predictive capacity for these
complications when compared to glycated hemoglobin, an AGE precursor
and already established risk factor for diabetic complications. This may be in
part due to AGEs’ ability to assess overall metabolic stress, rather than just
glucose metabolism (58).
Disease Prevention: The pathogenic functionality of AGEs is increased in
obese individuals. This could be the result of a combination of factors:
hyperglycemia, hyperlipidemia, increased consumption of AGE-rich foods,
etc (43). Obesity is, of course, a major risk factor for a variety of chronic
diseases, including breast cancer. Therefore, reduction of AGEs either
through decreased consumption of AGE-rich foods or through AGE/RAGE
inhibitors could have potential preventative implications in the development
and prognosis of several diseases.
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RESEARCH PLAN
Overall Rationale: Because of its pro-inflammatory nature, the AGE-RAGE signaling
axis has been previously implicated in the complication and progression of a variety
of chronic diseases including diabetes, cardiovascular disease, rheumatoid arthritis,
along with many others (54, 59). Only recently, however, has RAGE signaling been
shown to have tumorigenic effects in several different types of cancer. RAGE
signaling is able to activate a variety of kinase pathways including PI3K and MAPK
which are known to enhance proliferation and cell survival in cancer. Our lab has
previously shown an association between AGEs, RAGE, and disease progression in
prostate cancer (60). Because of this, we believe that AGE-RAGE signaling may be
serving this same functionality in breast cancer. Identifying a role for AGEs in breast
cancer may have potential therapeutic and preventative implications for patients
because of our ability to consume exogenous AGEs in the form of high fat, high
sugar, and thermally processed foods. Additionally, because a high AGE diet
promotes weight gain and obesity, implicating AGEs in breast cancer could
potentially explain the increase in incidence, reoccurrence and mortality that is
already known to be associated with obesity (43).
Around 70% of all invasive breast cancers express the estrogen receptor
(17). Activation of this receptor is the driving force behind the progression of these
types of cancer. Tamoxifen, which is often the first line of adjuvant therapy for these
patients, is an effective drug that combats the ability of the estrogen receptor to
enhance transcription of its target genes. A third of patients taking tamoxifen,
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however, will not respond to the drug and most who initially respond will develop
resistance. Several studies have attempted to find a molecular cause for this
acquired resistance by investigating specific, estrogen-independent
phosphorylation sites on the receptor itself (17, 25,
32, 61). Two sites in particular, ser167 and ser118
within the ligand independent activation domain,
have been suggested to influence tamoxifen
resistance. Ser167 and ser118 are phosphorylated
by the second messenger kinase pathways, PI3K and
MAPK, respectively. Because RAGE signaling has
Figure 9: Proposed
pathway by which AGEs
signal through RAGE to
influence ER+ breast
cancer progression and

already been shown to activate these signaling
cascades in other diseases, we believe that AGEs
could be a potential factor contributing to tamoxifen

resistant tumors by causing phosphorylation of the estrogen receptor at these two
residues through the PI3K and MAPK pathways. We are therefore proposing AGERAGE signaling (Figure 9) as a potential mechanism of progression and tamoxifen
resistance in estrogen receptor positive breast cancer.
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Hypothesis: We hypothesize that AGE levels are increased in breast cancer and
cause activation of cancer associated signaling pathways and contributes to the
development of tamoxifen resistance in estrogen receptor positive breast cancer.

Specific Aim #1: Determine whether or not presence of AGEs and RAGE are
indicative of disease progression in breast cancer. The RAGE signaling axis has
been implicated in a variety of diseases including diabetes, Alzheimer’s, and
cardiovascular disease. Additionally, RAGE signaling has been previously shown to
activate pro-survival and proliferative pathways in several types of cancer causing
its presence (along with AGEs) to be associated with increased grade and disease
progression in prostate, colorectal, and gastric cancers. Because of its protumorigenic ability, we believe identifying the RAGE signaling cascade as a marker
of increased breast cancer aggression will help elucidate its functional role in tumor
development and survival.
Task #1: Quantify AGE levels in breast cancer tissue and serum samples to
define:
1) Differences between normal, benign, and cancerous samples
2) Correlation between AGEs and level of differentiation as an
indicator of disease progression.
Task #2: Quantify RAGE levels in breast cancer tumor samples to define:
1) Differences between normal, benign, and cancerous samples

28

2) Correlation between RAGE protein level and tumor
differentiation as an indicator of disease progression.

Experimental Design
Biological Samples. Human serum samples (n=39) were obtained from MUSC’s
Tissue Biorepository. Tissue microarray was obtained from US BioMax (Rockville,
MD) and contained 96 samples of normal, benign, and cancerous tissue from 48
patients. Demographic data such as age and race were included. Pathological data
available from each patient included: tumor grade and receptor status (some).

AGE ELISA. In order to quantify AGE levels in serum samples from breast cancer
patients, a competitive ELISA assay was utilized to determine concentration of
circulating AGEs and comparisons were made based on level of tumor
differentiation as well as ER status. The OxiSelect™ Advanced Glycation End Product
Competitive ELISA kit was purchased from Cell Biolabs, Inc. (San Diego, CA). The
wells of the provided 96 well plate were coated with 5 ug/mL BSA-AGE conjugate
and incubated at 4°C overnight. Wells were then washed twice (250uL each) with
phosphate buffered saline (PBS) using an automatic plate washer (Bio-Tek
Instruments, Inc. Winooski VT). Plate was then blocked to prevent non-specific
binding using 200uL of assay diluent and incubated on an orbital shaker at room
temperature for one hour. After removal of diluent, 50uL of BSA-AGE standards or
serum samples were added to the wells in triplicate. Ten standards were prepared
29

according to the manufacturer’s instructions to produce serial dilutions ranging
from 1.56 ug/mL to 100 ug/mL. After addition of the sample, the plate was then
incubated at room temperature with light agitation for 10 minutes. 50uL of diluted
anti-AGE antibody (Cell Biolabs, Inc. San Diego, CA) was then added to each well and
allowed to incubate at room temperature with light agitation for 1 hour. Wells were
washed with 250uL of 1X wash buffer three times (Cell Biolabs, Inc. San Diego, CA)
using an automatic plate washer and thoroughly dried using absorbent strips.
100uL of diluted secondary antibody-horseradish peroxidase (HRP) conjugate (Cell
Biolabs, Inc. San Diego, CA) was added to each well and again allowed to incubate
for one hour at room temperature with light agitation. Plate was then washed in the
same manner described previously. 100uL of the substrate solution (Cell Biolabs,
Inc. San Diego, CA), after being warmed to room temperature, was added to each
well and incubated in the dark for fifteen minutes on an orbital shaker. To stop
enzymatic reaction, 100uL of stop solution (Cell Biolabs, Inc. San Diego, CA) was
added to each well and absorbance was read immediately on microplate reader
(Bio-Tek Instruments, Inc. Winooski, VT) using 450nm as the primary wavelength.

AGE/RAGE IHC. Quantification of AGEs within the tumors themselves was
accomplished using immunohistochemical (IHC) staining of the TMA. Because RAGE
is a transmembrane protein, expression levels are only quantifiable using IHC in
tumor samples. Tissue microarrays contained 96 total punched, paraffin embedded
samples, each 1mm in diameter mounted on glass slides 2mm apart. Removal of
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paraffin was accomplished by incubating slides at 60°C for 30-45 minutes. A series
of washes were then utilized in order to rehydrate the tissue samples: 2-xylene for
20 minutes each; 2-100% ethanol, 2-95% ethanol, 1-70% ethanol, and 1-50%
ethanol for ten minutes each; 3-distilled water for five minutes each. Vector
unmasking solution (Vector Labs, Burlingame, CA) was then used at a 1:100 dilution
for antigen retrieval. Slides were placed in a pap jar containing the diluted
unmasking solution and placed in a vegetable steamer, also containing diluted
unmasking solution, at 90°C for 30 minutes. The slides were then allowed to cool to
room temperature and placed in pap jar containing 0.3% hydrogen peroxide (Fisher
Scientific, Fair Lawn, NJ) for 30 minutes to remove any endogenous peroxidase
activity. The slides were then washed in 1x tris buffered saline containing 0.01%
Tween-20 (TBST) (Fisher Scientific, Fair Lawn, NJ) for 5 minutes on an orbital
shaker. In order to prevent solution run-off in the following steps, tissue samples
were outlined using a hydrophobic pen. Slides were then incubated in
VECTASTAIN® horse serum (Vector Labs, Burlingame, CA) to block non-specific
binding for 30 minutes at room temperature in a humidified chamber. Primary
antibodies for AGE and RAGE (Abcam, Cambridge, MA) were both diluted 1:50 using
horse blocking serum diluted with TBST and applied to respective slides and
allowed to incubate overnight at 4°C in a humidified chamber. Primary antibody
was then removed by washing 3 times in TBST for five minutes on an orbital shaker.
Slides were incubated with VECTASTAIN® secondary antibody solution (Vector
Labs, Burlingame, CA) for thirty minutes at room temperature in a humidified
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chamber. Slides were then washed as described previously. Next, slides were
incubated with immPACT™ NovaRED™ substrate solution (Vector labs, Burlingame,
CA) for 8 minutes and then placed in distilled water to stop enzymatic reaction.
Following a five minute wash in distilled water, slides were dehydrated in: 1-50%
ethanol for five minutes; 1-70% ethanol for five minutes; 2-95% ethanol for 5
minutes each; 2-100% ethanol for five minutes each; 2-xylene for 10 minutes each.
Glass cover slips were then mounted on top of slides using Permount® (Fisher
Scientific, Fair Lawn, NJ). Imaging was performed using an Olympus BH-2
microscope and DP 70 digital camera (Olympus American, Inc. Center Valley, PA).
Quantification of the staining of advanced glycation end products (AGEs) was
completed using a 0 to 4+ scoring method by a single pathologist. Each separate
tissue on the microarray was scored individually based on staining intensity where
0 was no staining of the cells of interest and 4+ was intense cytoplasmic staining.
The lowest score any tissue received in this series was 1+. To gain a score of 4+ the
staining had to be diffuse across the cells of interest. Each tissue was given a score
for both the epithelial component and the stromal component, when a stromal
component was present. Visual scoring for RAGE was used to quantify the staining
intensity in each IHC core sample. Reference samples were chosen and given a score
of 1 through 4 with 1 being the lowest and 4 being the highest staining intensity.
Scores were then assigned based upon the four reference samples.
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Analyses outlined in the tasks above were then performed in order to investigate
whether or not AGEs and RAGE are associated with a more aggressive disease in
breast cancer.

RNA Extraction and GLO1 mRNA Analysis. In order to quantify glyoxalase mRNA
in a panel of breast cancer cell lines and to gain insight into tumor detoxification of
AGE precursors, quantitative real time PCR was used. Cells were cultured on 10cm
plates and once 75% confluency was reached, media was aspirated and cells were
washed with 5mL of PBS. 1mL of Trypsin was then added to the plate and allowed to
incubate for five minutes to disrupt cell adhesion. 4mL of media was added in order
to neutralize the trypsin and then collected into a 15mL tube. The tube was
centrifuged at 1,000 RPM for 5 minutes to pellet the cells. The supernatant was then
aspirated and the cells were again washed with PBS. The tube was centrifuged once
more and again the supernatant was removed leaving only the pellet of cells. Total
RNA was extracted from the cell pellet using RNeasy® Plus Mini Kit (Qiagen,
Valencia, CA). 1ug of RNA was then reverse transcribed to produce cDNA using
iScript (BioRad, Hercules, CA) according to manufacturer’s instructions. The cDNA
was then diluted 1/20 using molecular grade water (Roche, Nutley, NJ). The cDNA
was used as a template for probe based, quantitative real-time PCR (RT-PCR) to
measure the total quantity of GLO1 mRNA (and GAPDH mRNA as control). Primers
were diluted 1/5 using molecular grade water (primer sequences shown in Table 1).
Probes for each mRNA transcript were obtained from the universal probe library
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(UPL) and RT-PCR was ran in a LightCycler480 (Roche, Nutley, NJ) with the
following conditions: after pre-incubation to 95°C, amplification occurred in a series
of 50 cycles of 5 seconds at 95°C then 30 seconds at 60°C. After 50 cycles, the plate
was cooled to 40°C. Each sample was run in triplicate and with corresponding
negatives (no cDNA in reaction mixture). The relative mRNA levels were quantified
using the Ct value measured against an internal standard curve using the software
provided by the instrument manufacturer (Roche, Nutley, NJ). Glyoxalase 1 mRNA
data obtained was then normalized to GAPDH mRNA data and analyzed.

Table 1: Primer Sequences for probe-based qRT-PCR
Gene
5' Primer
3' Primer
Probe #
RAGE
ggtcatcttggcaaag
cctcctcttcctcctggtt
23
Glyoxalase 1 cccagtaccaaggattttct tgggaaaatcacatttttgga
84
GAPDH
agccacatcgctcagacac gcccaatacgaccaaatcc
60
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Results and Discussion
AGEs exist in greater quantities in well differentiated serum samples: ELISA
assay data (Figure 9) suggests that well differentiated breast cancer patients have
higher circulating AGE levels when compared to the patients with a more
progressive, less differentiated disease. While this is not as we expected, a potential
explanation could be a difference in glyoxalase 1 activity in more aggressive
diseases. A recent paper cited that more aggressive, triple negative tumors exhibited
lower concentrations of AGE precursors, but greater glyoxalase 1 activity in both
tumor and tissue(62). Glyoxalase 1, as discussed previously, is an internal
detoxification mechanism that serves to lower concentrations of reactive carbonyls
within the cell. To attempt to verify this cited correlation between GLO1 and cancer
aggression, we quantified GLO1 mRNA in a panel of 8 breast cancer cell lines (Figure
11). On average, triple negative tumors had a greater level of GLO1 mRNA. Because
triple negative tumors are more aggressive than other subtypes, this data suggests
that more aggressive tumors are compensating rising AGE levels by increasing GLO1
activity. As can be seen in Table 2, the majority of the well differentiated serum
samples, as expected, were ER+/PR+/HER2- (Luminal). The poorly differentiated
samples however contained more samples with higher expression of HER2 (poor
prognostic factor) and more triple negative subtypes. As can be seen in the bottom
of Figure 10, when classified based on ER status, expression of the receptor is
indicative of a greater concentration of circulating AGEs in our patient samples.
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Figure 10 AGEs are increased in patients with well
differentiated, ER+ disease. ELISA assay data
quantifying circulating AGE levels in breast cancer
patient serum samples, classified based on level of
differentiation (top) and ER receptor status (bottom)
(n=39) (**, p<0.01).

Table 2. Receptor status of serum samples used for ELISA assay AGE
quantification. Well differentiated were mostly ER+ whereas poorly
differentiated samples were more heterogeneous in subtype.

ER+/PR+, HER2 ER+/PR+/HER2+
ER-/PR-/HER2+
Triple Negative
Unknown

Well Differentiated
(n=20)
12
0
0
1
7
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Poorly Differentiated
(n=19)
4
3
3
2
7
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Figure 11 GLO1 mRNA is increased in triple negative breast
cancer. qRT-PCR data quantifying glyoxalase 1 mRNA in panel of 8
breast cancer cell lines. Increased GLO1 is associated with more
aggressive, triple negative cell lines

AGEs and RAGE are increased in cancerous tumor samples:
Immunohistochemical staining of the tumor microarray for AGEs and RAGE
revealed that, on average, invasive carcinomas exhibited greater levels of AGEs and
RAGE protein within the tumor epithelium (Figure 12). Representative images are
shown in Figure 13. More intense staining was found in the tumor epithelium with
only slight staining within the tumor stroma for both AGE metabolites and RAGE
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protein. These data indicate that AGEs and RAGE are present and may potentially be
associated with increased malignancy in breast cancer.
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Figure 12 AGEs and RAGE are increased in cancerous tumor
samples. Quantification of immunohistochemical staining for AGEs
and RAGE in normal (n=3), benign breast hyperplasia (n=3), and
invasive breast cancer (n=29) shows increase in AGEs and RAGE with
increased malignancy. (****, p<0.0001, **, p<0.01)
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Figure 13 AGEs and RAGE are present in greater quantity in breast
cancer. Immunohistochemical staining of normal (top), benign
hyperplasia (middle), and invasive ductal carcinoma (bottom) for AGEs
(middle column) and RAGE protein (right column) with 20x magnification
(Inset-4x magnification). Highest level of AGEs are present in invasive
cancer when compared to benign conditions. RAGE protein is also
increased in cancerous tissue.

AGEs and RAGE are increased in poorly differentiated tumors:
Immunohistochemical staining of the tumor microarray for AGEs and RAGE
revealed that, on average, AGEs were indicative of less differentiation within the
tumor. Moderate and poorly differentiated tumors exhibited greater levels of AGEs
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within the tumor epithelium (Figure 14). Representative images are shown in
Figure 15. More intense staining was found in the tumor epithelium with only slight
staining within the tumor stroma for AGE metabolites. RAGE protein seemed to
trend towards being increased in more aggressive tumors but values were not
statistically significant. Again, these data indicate that AGEs (and potentially RAGE)
are indicative markers of a more advanced disease in breast cancer.
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Figure 14 AGEs and RAGE are associated with decreasing tumor
differentiation. Quantification of immunohistochemical staining for AGEs and
RAGE in malignant tumors separated by level of differentiation: well differentiated
(n=3), moderately differentiated (n=12), and poorly differentiated (n=16). Data
shows increase in AGEs with more advanced disease (*, p<0.05). RAGE seems to
trend toward same conclusion despite being statistically insignificant.

41

AGE

RAGE

Poor

Moderate

Well

H&E

Figure
1415
AGEs
and
RAGE
increase
with
lack
ofof
differentiation.
Figure
AGEs
and
RAGE
increase
with
lack
differentiation.
Immunohistochemical
staining
of
breast
carcinomas
with
varying
levels
ofof
Immunohistochemical staining of breast carcinomas
with
varying
levels
differentiation
forfor
AGEs
(middle
column)
and
RAGE
protein
(right
column)
differentiation
AGEs
(middle
column)
and
RAGE
protein
(right
with
20x
magnification
(Inset-4x
magnification).
Highest
level
of
AGEs
areof
column) with 20x magnification (Inset-4x magnification). Highest level
present
in poorly
differentiated
tissue whentissue
compared
better to better
AGEs are
present
in poorly differentiated
whentocompared
differentiated
tissues.
RAGE
protein
is
also
increased
(to
lesser
extent)
inin
differentiated tissues. RAGE protein is also increased (to lesser
extent)
poorly
differentiated
cancerous
tissue
indicating
both
are
potentially
poorly
differentiated
cancerous
tissue
indicating
both
are
potentially
associated
with
a
more
progressive
disease.
associated with a more advanced disease.
.

42

Discussion and alternative approaches
In this aim, we showed that AGEs are present in greater levels in serum
samples from patients with a less aggressive disease. Additionally, by looking at
tumor samples from breast cancer patients, we were able to show an increase
intratumoral AGEs and RAGE in cancerous tissue when compared to normal breast
and benign hyperplasia. Level of differentiation was also investigated and AGEs
were associated with more advanced tumors. RAGE showed a similar trend, but was
not statistically significant despite RAGE levels already having been shown to
correlate with a worsened prognosis in other cancers such as gastric and prostate
(63, 64). There are numerous possible explanations for the differences observed
between AGE serum and tumor correlations. One potential explanation is that the
tumors themselves are producing AGEs. This is plausible because of the high
glycolytic rate that is characteristic of malignant tumors and, as stated previously,
glycolytic intermediates are often precursors to AGE formation. This would explain
why we do not observe high AGE levels in more aggressive serum, but we see the
expected increase in the tumors themselves.
Observing AGEs and RAGE in greater levels within the malignant tumor when
compared to benign and normal breast tissue suggests that AGE-RAGE signaling
may be potentially contributing disease progression. This is reinforced in our data
showing increasing AGE levels in the moderate and poorly differentiated tumors
compared to the less progressed, well differentiated tumors. All of this data together
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suggests a possible role in breast cancer disease progression, but many more tasks
must be accomplished before reaching a final conclusion.
Identifying a role for AGEs in breast cancer could have potential preventative
implications. As can be seen in Table 2, the majority of the samples from patients
with well differentiated tumors were ER+ and exhibited higher AGE levels when
compared to the poorly differentiated tumors. As stated previously, ER+ positive
patients are often given the drug tamoxifen and many develop resistance. Specific
Aim 2 investigates AGEs in tamoxifen resistance and, by showing AGEs are
increased in serum for these patients, a low AGE diet and/or dual treatment with
AGE inhibitors may be beneficial for these patients.
A caveat with the experimental design in this specific aim is our small sample
size. While a tissue microarray allows for the testing of several tumor samples at
once, each sample is only a small representation of the tumor as a whole. The tumor
microenvironment is incredibly diverse and it is absolutely possible that AGEs and
RAGE are present and functioning in one part of the tumor to a greater extent than
in the remaining portion. A future direction for this aim would be to perform these
same tests in a much larger and more diverse sample size in order to gain a better
insight into the role of AGEs and RAGE in breast cancer tumor progression. Matched
serum and tumor samples would also be helpful in identifying a correlation between
circulating AGEs and intratumoral AGEs in a patient-specific manner. Additionally,
quantification of IHC staining is undoubtedly imperfect and it is important to keep in
mind that correlation does not necessarily imply causation. That is to say, even
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though we may see higher levels of RAGE within the higher grade tumors, RAGE
signaling may not be causing this progression. Because of this, it is necessary to
investigate the signaling pathway by which AGEs and RAGE are inducing this effect
in ER+ breast cancer.

45

Specific Aim #2: Determine if AGE-RAGE signaling through Akt and ERK
induces estrogen receptor phosphorylation leading to increased proliferation
and tamoxifen resistance. Previous studies have shown that RAGE signaling can
activate the specific kinase signaling cascades, PI3K and MAPK, which contribute to
tumor survival and growth in many cancers. Additionally and separately, previous
studies investigating a molecular cause for tamoxifen resistance in estrogen
receptor positive cancer have identified two residues on the receptor itself that,
when phosphorylated, are indicative of this resistance. Interestingly, these two
residues, ser167 and ser118, are phosphorylated by kinases within the PI3K and
MAPK pathways. This specific aim proposes that AGE signaling is connected to these
phosphorylation events and resistance to tamoxifen in ER+ breast cancer through
the mechanism shown in Figure 9. By characterizing this pathway, we can elucidate
a functional role of AGEs and RAGE in the development of this resistance.

Task #1: Determine AGE and RAGE levels in ER+ breast cancer cell lines in
order to:
1) Show that AGEs and RAGE are present in ER+ breast cancer
2) Create base line reading of AGE and RAGE protein levels before
manipulating pathway in following tasks
Task #2: Perform proliferation experiments following AGE treatment to
demonstrate:
1) AGEs role in cancer progression
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2) Gain a more functional perspective of AGEs and RAGE in breast
cancer in vitro
Task #3: Demonstrate that AGE-RAGE signaling induces phosphorylation of
the estrogen receptor on ser167 and ser118 through phosphorylation of Akt
and ERK 1/2 in order to:
1) Demonstrate AGEs signaling through RAGE activates protumorigenic signaling pathways
2) Create a connection between AGE-RAGE signaling and ER
mediated signaling in ER+ breast cancer
Task #4: Identify a role of AGEs in tamoxifen resistance by exposing ER+
cells to AGEs and monitoring cell viability during tamoxifen treatment to
determine if:
1) AGE-mediated activation of ER at ser167 and ser118 results in a
more resistant phenotype
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Experimental Design
Cell Culture. ER+ MCF7 and T47D cell lines were a gift from Dr. Dennis Watson at
the Medical University of South Carolina. Cells were incubated at 37°C, 5% CO₂ in
their respective media. T47D cells were incubated in RPMI (Fisher Scientific, Fair
Lawn, NJ) with 10% fetal bovine serum (Fisher Scientific, Fair Lawn, NJ), and 1%
Penicillin/Streptomycin (Fisher Scientific, Fair Lawn, NJ). MCF7 cells were
incubated in DMEM/High Glucose media (Fisher Scientific, Fair Lawn, NJ) also
containing 10% FBS and 1% Penicillin/Streptomycin with the following additives:
1% MEM Non-essential Amino Acids (Mediatech, Manassas, VA), 1% Sodium
Pyruvate (100mM) (Life Technologies, Grand Island, NY), 1% Sodium Bicarbonate
(7.5% stock) (Invitrogen, Grand Island, NY), and 1% insulin (Life Technologies,
Grand Island, NY). Media on each cell line was changed every 3 days and were
passaged once 75% confluency was reached using 0.05% HyClone Trypsin (Fisher
Scientific, Fair Lawn, NJ).

AGE and Protein Assessment. In order to assess endogenous AGE content in our
ER+ in vitro model, dot blot analysis was performed. RAGE, p-Akt (and total Akt), pERK1/2 (and total ERK), and p-ERα at both ser167 and ser118 (and total ERα)
expression were examined using Western Blot analysis. For each, cells were
cultured on 10cm plates. After reaching 75% confluency, the old media was
removed and plates were washed with 7mL of PBS. After removal of the PBS, cells
were lysed using 100uL RIPA lysis buffer +Halt phosphatase inhibitors (Pierce,
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Rockford, IL) and manually removed from the surface of the plate using a cell
scraper and placed into eppendorfs. Tubes were then centrifuged for 20 minutes at
13,000 RPM at 4°C. After centrifugation, the supernatant was collected and placed
into new eppendorfs. Protein concentration of each sample was then assessed using
the BCA protein assay (Pierce, Rockford, IL). A 2mg/mL standard of BSA was diluted
to 16ug/mL in 1% SDS and then serial diluted to produce the remaining samples for
the standard curve: 8ug/mL, 4ug/mL, 2ug/mL, 1mg/mL, and a blank of only 1%
SDS. 25uL of each standard was added into their respective wells on a 96 well plate
in duplicate. 5uL of the unknown samples were diluted into 20uL 1% SDS and then
added into their respective wells on the same plate. 200uL of the BCA protein assay
reagent (mixed according to manufacturer’s instructions) was added to each well.
The plate was incubated at 37° for thirty minutes, allowed to cool, and immediately
read on a spectrophotometer plate reader at a primary wavelength of 540nm (BioTek Instruments, Inc., Winooski, VT) to determine protein concentration of each
unknown sample. Samples were diluted to produce 50ug of protein using distilled
water.
For the western blot analysis, the diluted protein sample was added to a tube
containing Laemmli Sample Buffer (BioRad, Hercules, CA) plus 0.1% βmercaptoethanol and boiled for five minutes. The proteins in the samples were
separated using 10% Mini-PROTEAN® TGX (BioRad, Hercules, CA) pre-cast gels in
running buffer containing 25mM Tris-base, 192mM Glycine, and 1% SDS run at 200
volts for 45 minutes for blots investigating RAGE, Total Akt, ERK1/2, and ERα. For
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phosphorylated proteins (p-Akt, p-ERK1/2, and p- ERα), gels were run at 100 volts
for approximately two hours with the gel-containing chamber on ice. The protein
ladder, PageRuler Plus (BioRad, Hercules, CA), was used to estimate protein size.
Gels were removed from their casts and prepped for transfer to a PVDF (Millipore,
Billerica, MA) membrane that had been charged in methanol and rinsed in distilled
water. The blotting sandwich containing the gel and membrane was placed in a
chamber containing chilled transfer buffer (25mM Tris-base, 192mM Glycine, 20%
methanol). Transfer was performed at 100 volts for one hour for RAGE, Total Akt,
ERK1/2, and ERα. For phosphorylated proteins, transfer was performed at 40 volts,
on ice, for 90 minutes. Membranes were then removed and placed in 1x TBST
overnight at 4°C. To reduce non-specific binding, the membrane was blocked in
10% milk diluted in TBST for one hour. For phosphorylated proteins, the membrane
was blocked in 5% BSA diluted using TBST for one hour. After blocking, blots were
incubated with primary antibody at 4°C overnight with gentle agitation. Antibodies
were diluted as follows using either 5% milk or 2.5% BSA: RAGE (rabbit) (Abcam,
Cambridge, MA) 1:1500; p-Akt (rabbit) , p-ERK1/2 (rabbit), p- ERα ser167 (rabbit),
p- ERα ser118 (mouse) (Cell Signaling, Danvers, MA) 1:1000; Total Akt, Total
ERK1/2, Total ERα (Cell Signaling, Danvers, MA) 1:1000. Membranes were washed
three times in TBST for ten minutes each. Anti-rabbit and anti-mouse HRP linked
secondary antibodies (Cell Signaling, Danvers, MA) were then diluted in 5% milk or
2.5% BSA (1:4000 for all). Blots were incubated in appropriate secondary antibody
at room temperature for one hour on an orbital shaker. After washing excess
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secondary from the membrane (3 x 10 minutes each in TBST), Blots were covered
with Super Signal West Pico Chemoluminescence substrate (Fisher Scientific, Fair
Lawn, NJ) for 5 minutes in order to activate the horseradish peroxidase. Finally,
using autoradiography film (Delville Scientific, Metuchen, NJ) various time
exposures were taken of each blot and then developed on an automatic developer
(Kodak, Rochester, NY). After achieving ideal exposure, membranes were stripped
by washing with 200mM NaOH for five minutes, followed by two five minute washes
with distilled water in order to prepare membrane for loading control. Membranes
were blocked in 10% milk for thirty minutes and then incubated with GAPDH
primary antibody (Cell Signaling, Danvers, MA) at a 1:5000 dilution for two hours at
room temperature on an orbital shaker. Blots were then washed as before and
incubated with an anti-rabbit HRP linked secondary antibody (Cell Signaling,
Danvers, MA) diluted at 1:5000 for one hour at room temperature on an orbital
shaker. The blots were then washed and developed as described previously.
For the dot blot analysis, the diluted samples were boiled for five minutes.
10uL (50ug) of each sample was then carefully applied on a nitrocellulose
membrane in duplicate (one for AGE content and one for loading control) and
allowed to dry at room temperature for 90 minutes. The membrane was blocked in
5% BSA for thirty minutes. The blot was then incubated overnight at 4°C in primary
AGE antibody (Abcam, Cambridge, MA) diluted 1:4000 in 2.5% BSA. The membrane
was washed, incubated in secondary anti-body (1:10,000), and exposed to ECL in
the same manner as was detailed for the western blot analysis.
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RNA Extraction and RAGE mRNA Analysis. Endogenous RAGE mRNA as well as
change in RAGE mRNA following AGE treatment was performed using quantitative
real time PCR as previously described in Specific Aim #.1

Formation of Exogenous AGEs and AGE Treatments. In order to examine the
effects of AGEs on proliferation and estrogen receptor mediated signaling, we
needed to first produce exogenous AGEs that we could expose our ER+ cell lines to.
We chose to produce glyceraldehyde-derived AGEs because this type has been
shown to be biologically relevant (prevalent in total circulating AGEs) and also
enhances disease malignancy more so than other types of AGEs (i.e. glucose derived
AGEs) (65-67). Our protocol for production of these types of AGEs is as follows:
125mg BSA (Fisher Scientific, Fair Lawn, NJ) suspended in 3mL of distilled water,
1mL of 1M NaP (pH=7.4), 250uL of 2M glyceraldehyde (Fisher Scientific, Fair Lawn,
NJ), 31uL of 800mM diethylene triamine penta acetic acid (DENPA) (Fisher
Scientific, Fair Lawn, NJ), and then filled with distilled water to a total volume of
5mL. The solution was then incubated for seven days at 37°C with gentle agitation.
Following incubation, excess glyceraldehyde not conjugated to BSA was removed
using a dextran desalting column (Pierce, Rockford, IL) according to the
manufacturer’s instructions. Finally, the samples were concentrated to remove
excess PBS (used in previous step as exchange buffer) in 0.5mL centrifugal filter
units (Millipore, Billerica, MA) according to the manufacturer’s instructions. Final
AGE concentration was determined to be approximately 10mg/mL using an AGE
52

ELISA assay (described previously in specific aim #1). A control AGE solution was
made using the same protocol, but without glyceraldehyde in order to prevent any
glycation (and therefore no AGE formation) to ensure that the AGEs themselves are
causing an effect and not any of the other ingredient used in our AGE formation
process.
We then proceeded to treat our ER+ breast cancer cell lines with exogenous
AGEs. First, approximately 24 hours before cell collection was to occur, the cells’
media was changed to serum-free. After 24 hours of serum-starvation,
Glyceraldehyde AGEs were pipetted directly into the media for a final concentration
of 50ug/mL. The cells were then placed in a 37°C cell culture incubator for the time
specified for each experiment. The media containing the AGEs was then aspirated,
cells were washed with PBS, and cell collection proceeded as described previously.
Cells treated with the control AGE solution underwent the same treatment protocol.

Proliferation Assays. To look at the effects of AGE treatment on cell growth, a
proliferation assay was performed. Cells were plated in triplicate in a 96 well format
with 2,000 cells per well. Cells were allowed 24 hours to fully adhere to the bottom
of the plate. The zero time point was fixed using 5% cold trichloroacetic acid
incubated at 4°C for one hour. After incubation, the plate was washed four times
with water and stored until conclusion of experiment. The remaining cells were
either treated with 50ug/mL AGEs or left untreated and allowed to grow. The final
time point was then fixed at 48 hours using 10% cold TCA as described previously.
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Fixed plates were then stained with 0.4% sulforhodamine B diluted in 1% acetic
acid for 30 minutes at room temperature and washed four times with 1% acetic
acid. After allowing the plates to air dry, SRB staining was solubilized using 10mM
Tris Base for five minutes with gentle agitation and absorbance was immediately
read at 560nm using microplate reader (Bio-Tek Instruments Inc., Winooski, VT).
Percentage growth was then quantified by normalizing 48 hour time point with
corresponding zero time point.

shRNA Mediated Knockdown of RAGE Function. In order to verify that the proproliferative effect observed was dependent upon the presence of RAGE, shRNA was
used to stably knockdown RAGE in MCF7 cells. 150,000 MCF7 cells were plated into
the wells of a 12 well plate and allowed to adhere to the plate for 24 hours. Various
shRNA lentiviral vectors (Table 3) (Sigma-Aldrich CO. LLC, St. Louis, MO) were then
added to the appropriate well with an anticipated multiplicity of infection (MOI) of 2
along with polybrene (8ug/mL). 24 hours after infection, the media was changed
back to normal media. After 24 hours, media containing 2ug/mL puromycin was
added to each well in order to select only the cells that were infected with the
shRNA vector. After original selection, cells were cultured in media containing
200ng/mL puromycin. Knockdown of RAGE was verified using western blot
analysis.

54

Table 3: shRNA sequences for RAGE knockdown
Clone #
shRNA Sequence
165
CCGGGCGGCTGGAATGGAAACTGAACTCGAGTTCAGTTTCCATTCCAGCCGCTTTTTG
878
CCGGTGCTGATCCTCCCTGAGATAGCTCGAGCTATCTCAGGGAGGATCAGCATTTTTG
582
CCGGCACACTGCAGTCGGAGCTAATCTCGAGATTAGCTCCGACTGCAGTGTGTTTTTG
963
CCGGCCGTGCTGTCAGCATCAGCATCTCGAGATGCTGATGCTGACAGCACGGTTTTTG

Inhibition of Akt and ERK1/2. So that we may confirm AGE mediated activation of
the estrogen receptor is occurring through Akt and ERK1/2, we inhibited the
functionality of both kinases using the molecular inhibitors LY294002 and U0126,
respectively. MCF7 and T47D cells were cultured as described previously. Before
AGE treatment and subsequent cell collection, cells were treated with 15uM of the
appropriate inhibitor for 12 hours before being exposed to AGE treatment. Cells
were collected and subjected to western blot analysis for phosphorylated ERα as
described previously.

AGE Treatment and Tamoxifen Resistance. In order to investigate the effects of
AGE signaling on tamoxifen resistance, we performed a cell viability assay by plating
3,000 cells per well in triplicate on a 96 well plate. The cells were allowed 24 hours
to adhere to the plate and were then treated with varying doses of tamoxifen (0, 5,
10, 20uM) (Sigma Aldrich, St. Louis, MO) in combination with varying doses of AGEs
(5ug/mL, 10ug/mL, 50ug/mL). After 24, 48, and 72 hours, SRB staining was used to
quantify cell growth as described previously.
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Results and Discussion
AGEs and RAGE are present in two ER+ breast cancer cell lines: Dot blot
analysis shows baseline levels of AGEs present in MCF7 and T47D cell lines (Left,
Figure 16). Additionally, RAGE expression seems to be higher in the MCF7 cells
when compared to the T47D cells on both the protein and transcript level measured
by western blot and qRT-PCR analysis, respectively (Right, Figure 16). This also
happens to correlate with GLO1 mRNA levels observed in specific aim #1 (Figure
11). These data suggest that AGEs and RAGE are present in ER+ breast cancer.

AGE

RAGE mRNA

*

GAPDH
RAGE
GAPDH
Figure 16 AGEs and RAGE are present in two ER+ breast cancer cell lines.
Top Left) Dot blot analysis examining AGE content in BC cell lines. Top Right)
qRT-PCR data quantifying RAGE mRNA (normalized to GAPDH) in BC cell lines
showing a greater level of RAGE transcript in MCF7 cells (*, p<0.05), Bottom
Right) Western blot analysis of RAGE protein level confirming the greater
expression of RAGE in MCF7 when compared to T47D (GAPDH shown as
loading control).
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Figure 17 Exogenous AGE treatment increases RAGE mRNA and protein
expression: Top Panels) Western blot analysis showing increased expression of
RAGE protein following AGE treatment (50ug/mL) in MCF7 (left) and T47D (right)
cells. Bottom Panels) qRT-PCR data normalized to GAPDH examining increase in
RAGE mRNA following AGE treatment.
(*, p<0.05).

RAGE mRNA and protein are upregulated following AGE treatment: Following
AGE treatment (50ug/mL for 5 minutes) in both cell lines, RAGE mRNA (bottom
panels, Figure 17) and RAGE protein (top panels, Figure 17) were increased when
compared to untreated controls. Increase in RAGE mRNA was statistically significant
in MCF7 cells. The ability of our exogenous AGEs to upregulate the RAGE receptor is
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most likely a result of the positive feedback loop (discussed in background, Figure
8) and seeing these results indicate that we are able to manipulate the RAGE
signaling pathway for the following experiments.

AGEs signaling through RAGE result in more proliferative phenotype: To gain a
more functional perspective of the effects AGE-RAGE signaling has in ER+ breast
cancer, we performed proliferation assays because uncontrolled proliferation is
considered to be a hallmark of cancer. We utilized MCF7 and T47D cells and
examined proliferation after 48 hours with or without AGEs (50ug/mL). In both cell
lines, we found a statistically significant increase in growth in the presence of AGEs
when compared to the untreated control (Top, Figure18).
We then needed to determine if AGEs were signaling through RAGE to
produce this more proliferative phenotype. To do this, we utilized shRNA to stably
knockdown RAGE. We began with a variety of different clones including two
infections using a combination of shRNA. After successful infection and subsequent
puromycin selection, western blot analysis was used to verify knockdown (Middle,
Figure 18). We chose clone #165 as a partial knockdown model and #878 as an
almost total knockdown. A repeat western blot in our chosen clones verified our
results.
We performed the same proliferation assay as before to see if the increase in
proliferation that we observed was attenuated when AGEs were unable to interact
with the RAGE receptor (Bottom, Figure 18). In our scramble control, we observed
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the same increase in proliferation that we saw in our wild type MCF7 and T47D
cells. The RAGE knockdown clones, however, showed no difference between the
AGE treated and untreated cells indicating that RAGE is necessary for the AGEmediated increase in proliferation observed previously.

59

*
*

*

ns

MCF7

ns

Figure 18 AGE increases proliferation through interaction with RAGE receptor.
Top) Proliferation assay quantifying percentage growth after 48 hours in the
presence of AGEs (50ug/mL). Increased proliferation occurs with AGEs when
compared to untreated control (*, p<0.05). Middle) Western blot analysis verifying
shRNA mediated RAGE knockdown in MCF7 cells. Bottom) Proliferation assay in
stable RAGE knockdown cell line. Proliferation was unaffected despite presence of
AGEs (50ug/mL) in RAGE stable knockdowns (*, p<0.05).
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AGE treatment induces ERα phosphorylation: To begin examining AGEs
influence on estrogen receptor-mediated pathways, we first needed to look into the
effects on the estrogen receptor following AGE treatment. MCF7 and T47D cells
were treated with 50ug/mL of AGEs for 30 minutes and were then examined for
ser167 and ser118 phosphorylation. 100nM estradiol, one of the key estrogenic
ligands for the receptor was used as a positive control to ensure optimization of
phospho-specific antibodies. In both cell lines and at both serine residues, we found
a significant increase in phosphorylation following AGE treatment when compared
to untreated control (Figure 19). The estrogen independent phosphorylation of ERα
at these residues has been shown to be indicative of tamoxifen resistance. Our data
suggests that AGEs are capable of influencing these phosphorylation events, and
therefore potentially contributing to tamoxifen resistance.
Additionally, we examined the influence of different time durations of AGE
treatments on the phosphorylation of ERα at ser167 because of the transient nature
of this post-translational modification. We did indeed find a time dependent
activation of the receptor with a peak around 15-30 minutes following initial
treatment (Figure 20).
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Figure 19 AGE treatment induces ERα phosphorylation at ser167 and ser118.
MCF7 (left) and T47D (right) cells treated with either 100nM estradiol (positive
control) or with AGEs (50ug/mL) for 30 minutes. Western blot analysis using
phospho-specific ERα antibodies show greater phosphorylation of the receptor at
ser167 and ser118 following AGE treatment when compared to untreated control.
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Figure 20 Phosphorylation of ERα at ser167 occurs following AGE
treatment in a time-dependent manner. MCF7 (left) and T47D (right)
cells were treated with AGEs (50ug/mL) or with AGE control for varying
durations of time. Western blot analysis shows peak of phosphorylation
around 15-30 minutes following AGE treatment.
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AGE treatment induces Akt and ERK phosphorylation: Because we
hypothesized that RAGE was signaling through Akt and ERK to mediate estrogen
receptor phosphorylation, we needed to examine the effects of AGEs on activation of
both these kinases. To investigate this, we again treated MCF7 and T47D cells with
AGEs (50ug/mL) for varying time durations. In both cell lines, we found a
correlation between Akt (Figure 21) and ERK (Figure 22) phosphorylation and
duration of AGE treatment. The time-dependent manner in which these
phosphorylation events occur indicate that sustained exposure to AGEs may induce
pro-tumorigenic signaling pathways and influence estrogen-receptor mediated
signaling in ER+ breast cancer.
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Figure 21 AGE treatment induces phosphorylation of Protein Kinase B
(Akt) in a time-dependent manner. MCF7 (left) and T47D (right) cells were
treated with AGEs (50ug/mL) for varying time durations. Western blot
analysis shows correlation between Akt phosphorylation and duration of
treatment suggesting AGEs influence Akt activation in ER+ breast cancer.
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Figure 22 AGE treatment induces phosphorylation of ERK1/2 in a timedependent manner. MCF7 (left) and T47D (right) cells were treated with
AGEs (50ug/mL) for varying time durations. Western blot analysis shows
correlation between ERK phosphorylation and duration of treatment
suggesting AGEs influence ERK activation in ER+ breast cancer.
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Inhibition of Akt and ERK results in decreased ERα phosphorylation following
AGE treatment: To ensure that Akt and ERK were responsible for estrogen receptor
phosphorylation, we needed to inhibit these two kinases and examine downstream
effects. Using Ly294002, we successfully inhibited Akt phosphorylation (Figure 23)
in both MCF7 and T47D cell lines. Western blot analysis probing for p-ERα at ser167
revealed that, despite being exposed to AGEs (50ug/mL) for thirty minutes before
cell collection, little to no phosphorylation occurs when Akt is inhibited. We saw a
similar result when using U0126 to suppress ERK activation (Figure 24). When ERK
phosphorylation was successfully inhibited, phosphorylation of ERα at ser118 was
attenuated, even after AGE treatment. This suggests that AGEs, through interaction
with RAGE, signal through Akt and ERK to induce estrogen-independent activation
of the estrogen receptor.
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Figure 23 AGE-mediated ERα phosphorylation at ser167 is attenuated
following Akt inhibition. MCF7 (left) and T47D (right) cells treated with 15uM of
Akt inhibitor Ly294002 for 12 hours do not exhibit phosphorylation of the estrogen
receptor, despite 30 minute AGE treatment (50ug/mL). Cells treated with AGEs
alone do still exhibit increase in ser167 phosphorylation.
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Figure 24 AGE-mediated ERα phosphorylation at ser118 is attenuated
following ERK inhibition. MCF7 (left) and T47D (right) cells treated with
15uM of ERK inhibitor U0126 for 12 hours do not exhibit phosphorylation of
the estrogen receptor, despite 30 minute AGE treatment (50ug/mL). Cells
treated with AGEs alone do still exhibit increase in ser118 phosphorylation.
AGE treated cells are more resistant to tamoxifen: After identifying at least part
of the pathway by which AGEs induce ERα phosphorylation, we wanted to
investigate whether or not AGEs were, in fact, inducing tamoxifen resistance
through this mechanism. We examined this by performing a proliferation assay.
MCF7 and T47D cells were treated with varying levels of AGEs and varying levels of
tamoxifen and were allowed to grow for 24, 48, and 72 hours (Figures 25 and 26).
At the highest concentrations of tamoxifen (20uM), the 50ug/mL AGE treated cells
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still remained viable in both cell lines. Additionally, resistance to the effects of 20uM
tamoxifen occurred in an AGE dose-dependent manner in the MCF7 cells after 24
and 48 hours. Similar results occurred early on in the assay in the 5uM and 10uM
tamoxifen treated MCF7 cells. Response in T47D cells, however seemed to be more
dependent on AGE concentration later on in the assay in the 5uM and 10uM
tamoxifen treated cells. All of this data suggests that AGEs do, in fact, contribute to
tamoxifen resistance in vitro which may potentially occur by AGEs inducing ERα
phosphorylation at ser167 and ser118 through Akt and ERK, respectively.
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Figure 25 AGE treated MCF7 cells exhibit more resistant phenotype
following tamoxifen treatment. Proliferation assay showing percentage
growth in MCF7 cells treated with 5uM (top), 10uM (middle), and 20uM
(bottom) tamoxifen and with varying concentration of AGEs. AGE treated cells,
especially at higher concentrations, remained more viable when compared to
AGE untreated cells despite treatment with tamoxifen.
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Figure 26 AGE treated T47D cells exhibit more resistant phenotype
following tamoxifen treatment. Proliferation assay showing percentage growth
in T47D cells treated with 5uM (top), 10uM (middle), and 20uM (bottom)
tamoxifen with varying concentration of AGEs. AGE treated cells, especially at
higher concentrations, remained more viable when compared to AGE untreated
cells despite treatment with tamoxifen.
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Discussion and alternative approaches
The goal of this aim is to identify a role for AGE-RAGE signaling in ER+ breast
cancer progression and tamoxifen resistance. We have been able to determine that
AGEs and RAGE are normally present in the ER+ breast cancer cell lines MCF7 and
T47D. After exposing these two cell lines to AGEs, we have found that the expression
of RAGE is increased on both the transcript and protein levels. Additionally, we
showed that AGE treatment induces phosphorylation of ERα at ser167 and ser118
potentially through the activation of Akt and ERK, respectively. These two kinase
cascades are frequently altered in cancer and influence cell growth and survival.
Additionally, estrogen independent phosphorylation at these two residues are
significant because they have been previously identified as indicators of poor
clinical response to the SERM, tamoxifen. We have been able to show that AGEs do
possess the capability to alter tamoxifen response in vitro which may have very
important clinical implications in the future. In specific aim#1, we suggest that AGEs
and RAGE are associated with increased progression in breast cancer. Using a more
functional perspective with our breast cancer cell lines, we have shown AGE
treatment increases proliferation in wild type MCF7 and T47D cell lines because of
AGEs’ ability to interact with their receptor, RAGE. This may explain why we
observed an increased presence of AGEs and RAGE in the more progressed tumor
samples.
While our in vitro work is an important foundation in investigating a role for
AGEs in tamoxifen resistance, immortalized cell lines are not the ideal method for
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examining drug sensitivity because it fails to address the complexity of the tumor
microenvironment and intracellular signaling. We can only begin to scrape the
surface of the numerous signaling pathways that influence a tumor’s ability to grow
and metastasize within the mammalian body. Because of this shortcoming of our
model, in vivo mouse models in which tamoxifen treated mice are exposed to
exogenous AGEs will be necessary in the future to reliably identify any of the AGEmediated effects we observed in our cell lines.
In addition to the general failings of using an in vitro model to show clinically
relevant data, it is also important to recognize the complexity of intracellular
signaling itself. As stated previously, non-genomic action of ERα is a complex
network of bi-directional cross-talk so it is not reasonable to identify a linear
signaling pathway as we have suggested in this study. We can show this simple
pathway is occurring, but it is incredibly plausible that several other proteins may
be affecting the activation we are observing in our ER+ breast cancer cell lines.
Additionally, the disparity in peak phosphorylation between Akt/ERK and ERα may
indicate that ERα may be phosphorylating these kinases as well. Because of this,
suggesting that AGE signaling is the cause of all these effects is indeed
oversimplification.
Despite these shortcomings, we have shown data that suggests AGEs
signaling through RAGE is causing activation of the estrogen receptor independently
of estrogen, potentially leading to tamoxifen resistance through phosphorylation at
ser167 and ser118 in ER+ breast cancer.
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Future Experiments
While the data attained in this study suggests a functional role for AGEs in
breast cancer, many more studies need to be performed to reach a full conclusion.
As stated previously, our tissue and serum samples need to be expanded into a
wider set of patients with greater diversity. Doing so would allow us to investigate
AGE differences between varying demographics. As discussed previously, African
American women are more likely to die from their disease and it would be
interesting to investigate a role for AGEs in this disparity. Additionally, since the
focus of our study is on ER+ breast cancer for the most part, focusing in on this
specific subtype would allow us to gain insight into the role of AGEs in specific ER+
disease progression.
Characterizing the specific signaling pathway by which AGEs influence
tamoxifen sensitivity requires more gain of function and loss of function studies. By
investigating knockdown and overexpression of RAGE protein in our tamoxifen
treated cells, we can verify that the AGE mediated tamoxifen resistance is occurring
because of RAGE signaling. It would also be important to investigate ERα signaling
using immunofluorescence. It is known that the estrogen receptor can be located
throughout the cell and its functionality can be dependent upon its location. It would
be interesting to identify where the receptor is localizing following AGE treatment in
order to gain more insight into exactly how AGEs are inducing these
phosphorylation events. And, if we observe nuclear localization, identifying which
target genes are being transcribed will allow us to gain a functional perspective as to
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how increased proliferation and tamoxifen resistance are occurring. Additionally,
several studies have documented development of tamoxifen resistant cell lines.
Usage of such a cell line could allow us to examine basal levels of AGEs in these cells
compared to tamoxifen sensitive cells as well as the effects of AGE inhibitors on
rescuing tamoxifen sensitivity. Finally, breast cancer patients can also exhibit
resistance to aromatase inhibitors, so it would be ideal to investigate whether or not
AGEs are contributing to this phenotype as well.
A key goal to further the knowledge gained in this project is to investigate
this signaling pathway in an in vivo model. It would be ideal to look at the effects of
a high AGE diet on tamoxifen resistance in a breast cancer mouse model because of
its preventative and clinical implications.

Significance of study
Previously, several studies have implicated AGEs in the pathogenesis of a
variety of different diseases including diabetes, cardiovascular disease, and
Alzheimer’s. AGE-RAGE signaling has only recently been shown to contribute to
tumorigenic signaling in cancers such as colorectal, prostate, and pancreatic. Very
little research, however, has investigated the effects of AGE and RAGE signaling in
breast cancer. It is important to elucidate the role of these reactive metabolites in
breast cancer disease progression because of our ability to consume exogenous
AGEs. By showing that high levels of AGEs leads to a more progressed disease, our
data could potentially possess preventative implications in breast cancer. It is
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already known that obesity is a risk factor for development and reoccurrence in
breast cancer and our data could possibly offer a mechanistic explanation for this.
In addition to simply showing this association between AGEs and breast
cancer progression, identifying a mechanism for tamoxifen resistance is both a
widely investigated and severely misunderstood field of study. About 70% of all
invasive breast cancers express the estrogen receptor, making it of utmost
importance to create more effective treatments for these patients. By characterizing
a functional role of AGEs in the development of tamoxifen resistance, targeted
therapies for this type of cancer can potentially become more effective, leading to an
improved prognosis. This could occur through modification of diet or through AGE
inhibition with drugs already on the market in tamoxifen treated patients. Many
studies have shown an association between certain estrogen independent
phosphorylation sites on ERα. Here, we have shown that two of these identified
residues are activated in response to AGE exposure and that AGE treatment reduces
cell sensitivity to tamoxifen treatment. By identifying an effect on sensitivity to this
drug, we can add to the existing knowledge base that is reinforcing the need for
more personalized medicine in cancer.
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